MARKET

NBIX

NBIX

Neurocrine Biosciences Inc
NASDAQ
134.66
-1.27
-0.93%
After Hours: 132.00 -2.66 -1.98% 19:30 04/12 EDT
OPEN
136.22
PREV CLOSE
135.93
HIGH
137.78
LOW
134.63
VOLUME
577.34K
TURNOVER
0
52 WEEK HIGH
148.37
52 WEEK LOW
89.04
MARKET CAP
13.54B
P/E (TTM)
54.47
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Summit Therapeutics (SMMT) and Neurocrine (NBIX)
TipRanks · 2d ago
Where Neurocrine Biosciences Stands With Analysts
Neurocrine Biosciences has an average price target of $153.78. The company is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. 9 analysts have published ratings on the company in the last three months. The average 12-month price target for the company is $200.00.
Benzinga · 3d ago
Neurocrine Price Target Maintained With a $155.00/Share by Cantor Fitzgerald
Dow Jones · 3d ago
Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
TipRanks · 4d ago
Weekly Report: what happened at NBIX last week (0401-0405)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neurocrine (NBIX)
TipRanks · 5d ago
NEUROCRINE BIOSCIENCES INC <NBIX.O>: RBC RAISES TARGET PRICE TO $136 FROM $129
Reuters · 04/04 11:37
More
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Webull offers Neurocrine Biosciences, Inc. stock information, including NASDAQ: NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.